Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
FullHope Biomedical CoROCO:7773 +2.84%22 Days Payable is 38.33 as of Jun. 2026, which is 56% below its 10-year median of 87.14. GuruFocus rates ROCO:7773 with a GF Score™ of 22/100. The stock has 2 warning signs investors should review. Among 708 Biotechnology companies, FullHope Biomedical Co ranks worse than 70.2% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:7773 vs VRTX, REGN, RVMD: Days Payable Comparison
For the Biotechnology subindustry, FullHope Biomedical Co's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
FullHope Biomedical Co Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, FullHope Biomedical Co's Days Payable distribution charts can be found below:
* The bar in red indicates where FullHope Biomedical Co's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
FullHope Biomedical Co's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FullHope Biomedical Co (ROCO:7773) has a Days Payable of 38.33 as of Jun. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on FullHope Biomedical Co and its competitors. This is 56% below median its historical median of 87.14. Over the past decade, FullHope Biomedical Co's Days Payable has ranged from 44.63 to 135.16. According to the industry distribution chart, FullHope Biomedical Co ranks #497 out of 708 companies in the Biotechnology industry, placing it in the top 70.2%.
Is FullHope Biomedical Co's Days Payable too high?
FullHope Biomedical Co's current Days Payable of 38.33 is 56% below median its 10-year median of 87.14. Over the past 10 years, this metric has ranged from a low of 44.63 to a high of 135.16. The Biotechnology industry median Days Payable is 111.17. FullHope Biomedical Co's value of 38.33 is 65.5% below this industry median. Based on the distribution chart, FullHope Biomedical Co ranks #497 out of 708 companies in the Biotechnology industry, which is below the industry midpoint. Overall, FullHope Biomedical Co has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does FullHope Biomedical Co's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, FullHope Biomedical Co ranks #497 out of 708 companies for Days Payable. This places FullHope Biomedical Co in the lower half of its industry. The industry median Days Payable is 111.17. FullHope Biomedical Co's value of 38.33 is 65.5% below this benchmark. Historically, FullHope Biomedical Co's own Days Payable has ranged from 44.63 to 135.16 over the past decade. While the company's 10-year median is 87.14 vs. the industry median of 111.17, FullHope Biomedical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 111.17, based on 708 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. FullHope Biomedical Co's current Days Payable of 38.33 is 65.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on FullHope Biomedical Co and its competitors. For the Biotechnology industry, the median Days Payable is 111.17 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. FullHope Biomedical Co's current Days Payable is 38.33, which is 56% below median its own 10-year median of 87.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is FullHope Biomedical Co stock overvalued right now?
FullHope Biomedical Co (ROCO:7773) has a current Days Payable of 38.33. The current Days Payable is 38.33, which is 56% below median its 10-year median of 87.14 and 65.5% below the Biotechnology industry median of 111.17. FullHope Biomedical Co's overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For FullHope Biomedical Co (ROCO:7773), the current Days Payable is 38.33 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
FullHope Biomedical Co Ltd focuses on immune system-related services and innovative R&D. It establishes cell-based immunotherapies for cancers and autoimmune disorders. Its services are, Immunoprofiling, Circulating Tumor Cells Testing, Regulation of Cell Therapy, Contracting Immune Cell Manufacturing, Immune Cell Bank, Contract Research Organization, and Endotoxin and Mycoplasma Detection Service.
22GF Score
Get the complete analysis for ROCO:7773
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7773 has been successfully added to your 
